We therefore believe that we now have sufficient funding to achieve this important milestone, as well as to continue to support the ongoing Phase 2 clinical trial of AGS-004 in combination with vorinostat targeting HIV eradication in adult patients.”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.